Exscientia plc (0RK.SG)

4.1400 +0.0600 (+1.47%) At close: 07:29PM CEST

Exscientia plc

The SchrOedinger Building
Oxford Science Park
Oxford OX4 4GE
United Kingdom
44 18 6581 8941
https://www.exscientia.ai

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 483

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David Hallett Ph.D.	Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director	N/A	N/A	1969
Mr. Ben R. Taylor	CFO, Chief Strategy Officer & Executive Director	499.31k	N/A	1977
Dr. John P. Overington Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Ms. Sara Sherman	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Dan Ireland	Executive VP of Legal & Company Secretary	N/A	N/A	N/A
Mr. Parker Moss	Executive Vice President of Corporate Development	N/A	N/A	N/A
Ms. Caroline Rowland	Chief People Officer	N/A	N/A	N/A
Mr. Richard Law	Chief Business Officer	N/A	N/A	N/A
Mr. Nikolaus Krall	Executive Vice President of Precision Medicine	N/A	N/A	N/A
Dr. Marie-Louise Helena Fjallskog M.D., Ph.D.	Interim Chief Medical Officer & Clinical Development Lead	N/A	N/A	1964

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité – Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Corporate governance

Exscientia plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.